Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication

Vascular and Endovascular Surgery

Volumn 48, Issue 3, 2014, Pages 224-229

  Lee, Constance ^a   Nelson, Peter R ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

cilostazol; intermittent claudication; peripheral arterial disease

Indexed keywords

CILOSTAZOL; CYTOCHROME P450 INHIBITOR; PENTOXIFYLLINE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICATION COMPLIANCE; NAUSEA; OUTCOME ASSESSMENT; PRESCRIPTION; PROGRAM EFFECTIVENESS; RETROSPECTIVE STUDY; SMOKING CESSATION; THORAX PAIN; TREATMENT REFUSAL;

CILOSTAZOL; INTERMITTENT CLAUDICATION; PERIPHERAL ARTERIAL DISEASE;

AGED; EXERCISE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; SMOKING CESSATION; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896803692     PISSN: 15385744     EISSN: 19389116     Source Type: Journal    
DOI: 10.1177/1538574413518121     Document Type: Article

References (22)

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the national health and nutrition examination survey, 1999-2000. Circulation. 2004 ; 110 (6). 738-743
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the American association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; TransAtlantic inter-society consensus; and vascular disease foundation. Circulation. 2006 ; 113 (11). e463 - e654
3. Comerota AJ. Endovascular and surgical revascularization for patients with intermittent claudication. Am J Cardiol. 2001 ; 87 (12A). 34D - 43D
4. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007 ; 45 (suppl S). S5 - S67
5. Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982 ; 69 (suppl). S24 - S26
6. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987 ; 221 (3). 253-260
7. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 ; 142 (4). 233-239
8. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995 ; 274 (12). 975-980
9. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006 ; (2). CD005263
10. O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009 ; 49 (5). 1226-1234
11. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001 ; 344 (21). 1608-1621
12. Dobesh PP, Stacy ZA, Persson EL. Pharmacologic therapy for intermittent claudication. Pharmacotherapy. 2009 ; 29 (5). 526-553
13. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001 ; 87 (12A). 28D - 33D
14. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med. 1991 ; 325 (21). 1468-1475
15. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999 ; 159 (17). 2041-2050
16. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000 ; 109 (7). 523-530
17. Strandness DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002 ; 36 (2). 83-91
18. Marshall C, Lin PH, Huynh TT, Kougias P. How optimal is the medical management of patients prior to major reconstructive vascular surgery? the results of a cross-sectional study. Vasc Endovascular Surg. 2009 ; 43 (3). 238-243
19. McDermott MM, Liu K, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA. 2004 ; 292 (4). 453-461
20. Barak S, Stopka CB, Archer Martinez C, Carmeli E. Benefits of low-intensity pain-free treadmill exercise on functional capacity of individuals presenting with intermittent claudication due to peripheral arterial disease. Angiology. 2009 ; 60 (4). 477-486
21. Nicolai SP, Kruidenier LM, Rouwet EV, Graffius K, Prins MH, Teijink JA. The walking impairment questionnaire: an effective tool to assess the effect of treatment in patients with intermittent claudication. J Vasc Surg. 2009 ; 50 (1). 89-94
22. Ware JE, Kosinski M, Keller SD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care. 1996 ; 34 (3). 220-233